6 months ago
TVTX
AnalystsGreg HarrisonGreg Harrison's Stock Forecasts
AnalystsGreg Harrison
Analyst Ranking
Bottom 15%
#4150 out of 4862 analysts
Average Return
-2.54%
Win Rate
35%22 out of 63
Risk vs Reward
Poor
Good
Greg Harrison's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iveric Bio IncISEE | +244.89% | $11.25 | $38.80 | 2022-06-07 - 2023-06-07 | Strong Buy |
Liquidia CorpLQDA | +117.00% | $4.03 | $8.75 | 2022-05-25 - 2023-05-25 | Strong Buy |
Rocket Pharmaceuticals IncRCKT | +96.61% | $21.84 | $42.94 | 2020-06-24 - 2021-06-25 | Strong Buy |
Travere Therapeutics IncTVTX | +93.76% | $7.85 | $15.21 | 2023-09-21 - 2024-09-20 | Strong Buy |
Athersys IncATHXQ | +83.21% | $5.35 | $0.90 | 2022-05-22 - 2023-05-22 | Sell |
Greg Harrison Analyst Color
Get additional color on Greg Harrison's coverage of popular stocks
8 months ago
TVTX
2 years ago
NTLA
Greg Harrison's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
United Therapeutics CorpUTHR | 1 | Hold | $314.00 | +10.47% | Upgrades | a day ago |
Apellis Pharmaceuticals IncAPLS | 3 | Hold | $31.00 | +71.94% | Maintains | 20 days ago |
Travere Therapeutics IncTVTX | 9 | Strong Buy | $31.00 | +105.16% | Maintains | 21 days ago |
Alnylam Pharmaceuticals IncALNY | 5 | Buy | $342.00 | +46.94% | Maintains | 22 days ago |
Liquidia CorpLQDA | 5 | Buy | $34.00 | +155.83% | Maintains | a month ago |
Beam Therapeutics IncBEAM | 5 | Buy | $40.00 | +119.30% | Upgrades | a month ago |
Rocket Pharmaceuticals IncRCKT | 4 | Buy | $52.00 | +625.24% | Maintains | 2 months ago |
Disc Medicine IncIRON | 4 | Buy | $75.00 | +78.32% | Maintains | 2 months ago |
Geron CorpGERN | 2 | Buy | $4.00 | +196.30% | Maintains | 2 months ago |
Bridgebio Pharma IncBBIO | 5 | Buy | $52.00 | +55.18% | Maintains | 2 months ago |
Vertex Pharmaceuticals IncVRTX | 5 | Hold | $450.00 | -5.76% | Maintains | 2 months ago |
Keros Therapeutics IncKROS | 5 | Buy | $41.00 | +186.71% | Maintains | 3 months ago |
Agios Pharmaceuticals IncAGIO | 4 | Buy | $75.00 | +174.32% | Maintains | 4 months ago |
Vera Therapeutics IncVERA | 1 | Buy | $60.00 | +184.23% | Initiates Coverage On | 6 months ago |
Eyepoint Pharmaceuticals IncEYPT | 1 | Buy | $18.00 | +205.08% | Initiates Coverage On | 6 months ago |
Ocular Therapeutix IncOCUL | 1 | Buy | $22.00 | +189.09% | Initiates Coverage On | 6 months ago |
Editas Medicine IncEDIT | 3 | Strong Buy | $15.00 | +1,027.82% | Upgrades | 8 months ago |
Intellia Therapeutics IncNTLA | 2 | Strong Buy | $91.00 | N/A | Maintains | 2 years ago |
Stoke Therapeutics IncSTOK | 3 | Hold | $12.00 | N/A | Upgrades | 2 years ago |
Sangamo Therapeutics IncSGMO | 1 | Sell | $1.50 | N/A | Downgrades | 2 years ago |
Mineralys Therapeutics IncMLYS | 1 | Strong Buy | $39.00 | N/A | Initiates Coverage On | 2 years ago |
Omeros CorpOMER | 1 | Sell | $3.00 | N/A | Downgrades | 2 years ago |
Senti Biosciences IncSNTI | 1 | Strong Buy | $70.00 | N/A | Initiates Coverage On | 3 years ago |
Neurogene IncNGNE | 2 | Sell | $5.00 | N/A | Downgrades | 3 years ago |
Radius Health IncRDUS1 | 1 | Hold | $8.00 | N/A | Upgrades | 3 years ago |
Iveric Bio IncISEE | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | 3 years ago |
Athersys IncATHXQ | 4 | Sell | $6.25 | N/A | Downgrades | 3 years ago |
Sentinelone IncS | 1 | Strong Buy | $54.00 | N/A | Maintains | 3 years ago |
Nektar TherapeuticsNKTR | 2 | Sell | $6.00 | N/A | Downgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.